

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A denatured laminin selective peptide antagonist.
2. (Previously presented) The antagonist of claim 1 wherein the antagonist is a peptide comprising an amino acid sequence NH₂-S-T-Q-N-A-S-L-L-S-L-T-V-C-COOH (SEQ ID NO 1).
3. (Previously presented) The antagonist of claim 1 wherein the antagonist is a peptide comprising an amino acid sequence NH₂-K-G-G-C-S-T-Q-N-A-Q-L-L-S-L-I- V-G-K-A-COOH (SEQ ID NO 2).
4. (Previously presented) The antagonist of claim 1 wherein the antagonist is a peptide comprising an amino acid sequence NH₂-K-G-G-S-T-Q-N-A-Q-L-L-S-L-I-V- G-K-A-COOH (SEQ ID NO 3).
5. (Original) The antagonist of claim 1 wherein the binding affinity of the denatured laminin selective antagonist to denatured laminin is substantially greater than the binding affinity of said antagonist to native laminin.
6. (Original) The antagonist of claim 1 wherein the binding affinity of the denatured laminin selective antagonist to denatured laminin is 100-fold greater than the binding affinity of said antagonist to native laminin.
7. (Original) The antagonist of claim 1 wherein the denatured laminin selective antagonist inhibits cellular interaction with denatured laminin.
8. (Original) A pharmaceutical composition comprising a denatured laminin selective antagonist and a pharmaceutically acceptable excipient.
9. (Original) The pharmaceutical composition of claim 8 wherein the composition comprises a cytotoxic agent.
10. (Original) The pharmaceutical composition of claim 8 wherein the composition comprises a radioactive material.
11. (Original) The pharmaceutical composition of claim 8 wherein the composition comprises a cytostatic agent.
- 12-36 (Canceled)